The case for routine parathyroid hormone monitoring

Stuart M. Sprague, Sharon Moe

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Parathyroid hormone (PTH) is a uremic toxin with multiple systemic effects including bone disorders (renal osteodystrophy), myopathy, neurologic abnormalities, anemia, pruritus, and cardiomyopathy. Hyperparathyroidism is common in CKD and results in significant morbidity and mortality if left untreated. Clinical practice guidelines from the Kidney Disease Improving Global Outcomes initiative broadened the optimal PTH range to >2 and <9 times the upper limit of normal for the assay measured. Furthermore, the guidelines recommend following trends in PTH to determine the appropriate therapy. These guidelines overcome issues with the assay variability and help clinicians make judgments when treating individual patients. They also require frequent measurement in order to determine trends and implement appropriate treatments.

Original languageEnglish
Pages (from-to)313-318
Number of pages6
JournalClinical Journal of the American Society of Nephrology
Volume8
Issue number2
DOIs
StatePublished - Mar 7 2013

Fingerprint

Parathyroid Hormone
Guidelines
Nervous System Malformations
Chronic Kidney Disease-Mineral and Bone Disorder
Hyperparathyroidism
Kidney Diseases
Muscular Diseases
Pruritus
Cardiomyopathies
Practice Guidelines
Anemia
Morbidity
Bone and Bones
Mortality
Therapeutics

ASJC Scopus subject areas

  • Nephrology
  • Transplantation
  • Epidemiology
  • Critical Care and Intensive Care Medicine

Cite this

The case for routine parathyroid hormone monitoring. / Sprague, Stuart M.; Moe, Sharon.

In: Clinical Journal of the American Society of Nephrology, Vol. 8, No. 2, 07.03.2013, p. 313-318.

Research output: Contribution to journalArticle

@article{bf68cca9b4074bfdb370096c57da1ef1,
title = "The case for routine parathyroid hormone monitoring",
abstract = "Parathyroid hormone (PTH) is a uremic toxin with multiple systemic effects including bone disorders (renal osteodystrophy), myopathy, neurologic abnormalities, anemia, pruritus, and cardiomyopathy. Hyperparathyroidism is common in CKD and results in significant morbidity and mortality if left untreated. Clinical practice guidelines from the Kidney Disease Improving Global Outcomes initiative broadened the optimal PTH range to >2 and <9 times the upper limit of normal for the assay measured. Furthermore, the guidelines recommend following trends in PTH to determine the appropriate therapy. These guidelines overcome issues with the assay variability and help clinicians make judgments when treating individual patients. They also require frequent measurement in order to determine trends and implement appropriate treatments.",
author = "Sprague, {Stuart M.} and Sharon Moe",
year = "2013",
month = "3",
day = "7",
doi = "10.2215/CJN.04650512",
language = "English",
volume = "8",
pages = "313--318",
journal = "Clinical journal of the American Society of Nephrology : CJASN",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "2",

}

TY - JOUR

T1 - The case for routine parathyroid hormone monitoring

AU - Sprague, Stuart M.

AU - Moe, Sharon

PY - 2013/3/7

Y1 - 2013/3/7

N2 - Parathyroid hormone (PTH) is a uremic toxin with multiple systemic effects including bone disorders (renal osteodystrophy), myopathy, neurologic abnormalities, anemia, pruritus, and cardiomyopathy. Hyperparathyroidism is common in CKD and results in significant morbidity and mortality if left untreated. Clinical practice guidelines from the Kidney Disease Improving Global Outcomes initiative broadened the optimal PTH range to >2 and <9 times the upper limit of normal for the assay measured. Furthermore, the guidelines recommend following trends in PTH to determine the appropriate therapy. These guidelines overcome issues with the assay variability and help clinicians make judgments when treating individual patients. They also require frequent measurement in order to determine trends and implement appropriate treatments.

AB - Parathyroid hormone (PTH) is a uremic toxin with multiple systemic effects including bone disorders (renal osteodystrophy), myopathy, neurologic abnormalities, anemia, pruritus, and cardiomyopathy. Hyperparathyroidism is common in CKD and results in significant morbidity and mortality if left untreated. Clinical practice guidelines from the Kidney Disease Improving Global Outcomes initiative broadened the optimal PTH range to >2 and <9 times the upper limit of normal for the assay measured. Furthermore, the guidelines recommend following trends in PTH to determine the appropriate therapy. These guidelines overcome issues with the assay variability and help clinicians make judgments when treating individual patients. They also require frequent measurement in order to determine trends and implement appropriate treatments.

UR - http://www.scopus.com/inward/record.url?scp=84875030925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875030925&partnerID=8YFLogxK

U2 - 10.2215/CJN.04650512

DO - 10.2215/CJN.04650512

M3 - Article

C2 - 23037984

AN - SCOPUS:84875030925

VL - 8

SP - 313

EP - 318

JO - Clinical journal of the American Society of Nephrology : CJASN

JF - Clinical journal of the American Society of Nephrology : CJASN

SN - 1555-9041

IS - 2

ER -